Hormonal Açidan Endometriyozis

Translated title of the contribution: Endometriosis: A Hormonal Approach

Bilgin Gürateş, Ekrem Sapmaz, Gokhan Kilic, Hüsnü Çelik

Research output: Contribution to journalArticle

Abstract

Estrogen is an extremely potent mitogen for endometrium and endometriosis. The product of a single gene named aromatase, synthesizes estrogen. Aromatase is the rate-limiting enzyme for the conversion of C19 steroids to estrogens in a number of human tissues including the ovary. Additionally, the pathologic estrogen-dependent tissues such as breast cancer and endometriosis also produce significant levels of aromatase and local estrogen. The clinical significance of local aromatase activity in endometriotic tissue was exemplified recently by the successful use of an aromatase inhibitor to treat an unusually aggressive and resistant case of recurrent postmenopausal endometriosis. Therefore, aberrant aromatase expression in endometriotic tissue, in contrast to eutopic endometrium, accounts for local biosynthesis of estrogen that promotes the growth of these lesions. The potent estrogen, estradiol is metabolized and thus inactivated by an enzyme termed 17β-hydroxysteroid dehydrogenase (HSD) type 2. Progesterone action is mediated by its receptor subtypes, progesterone receptor (PR)-A and PR-B. Progesterone, on the other hand, inhibits the mitogenic action of estrogen on endometrium and enhances differentiation. These antiproliferative and differentiative effects of progesterone are less pronounced on endometriotic tissue compared with endometrium. Thus, endometriosis is, at least in part, resistant to progesterone action. A number of abnormalities has been found in the expression of aromatase, 17β-HSD type 2 and PR-B/PR-A ratio in endometriotic tissue. These abnormalities and their functional consequences will be discussed in this review article.

Original languageUndefined
Pages (from-to)196-203
Number of pages8
JournalJinekoloji ve Obstetrik Dergisi
Volume17
Issue number4
StatePublished - Dec 2003
Externally publishedYes

Fingerprint

Endometriosis
Aromatase
Estrogens
Endometrium
Progesterone
Aromatase Inhibitors
Enzymes
Mitogens
Ovary
Estradiol
Steroids
Breast Neoplasms
Growth
Genes

Keywords

  • 17β-hydroxysteroid Dehydrogenase type 2
  • Aromatase
  • Aromatase Inhibitors
  • Endometriosis
  • Endometrium
  • Estradiol
  • Estrogen
  • Estrogen Biosynthesis
  • Estrogen metabolism
  • Estrone
  • Progesterone
  • Progesterone receptors

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Gürateş, B., Sapmaz, E., Kilic, G., & Çelik, H. (2003). Hormonal Açidan Endometriyozis. Jinekoloji ve Obstetrik Dergisi, 17(4), 196-203.

Hormonal Açidan Endometriyozis. / Gürateş, Bilgin; Sapmaz, Ekrem; Kilic, Gokhan; Çelik, Hüsnü.

In: Jinekoloji ve Obstetrik Dergisi, Vol. 17, No. 4, 12.2003, p. 196-203.

Research output: Contribution to journalArticle

Gürateş, B, Sapmaz, E, Kilic, G & Çelik, H 2003, 'Hormonal Açidan Endometriyozis', Jinekoloji ve Obstetrik Dergisi, vol. 17, no. 4, pp. 196-203.
Gürateş B, Sapmaz E, Kilic G, Çelik H. Hormonal Açidan Endometriyozis. Jinekoloji ve Obstetrik Dergisi. 2003 Dec;17(4):196-203.
Gürateş, Bilgin ; Sapmaz, Ekrem ; Kilic, Gokhan ; Çelik, Hüsnü. / Hormonal Açidan Endometriyozis. In: Jinekoloji ve Obstetrik Dergisi. 2003 ; Vol. 17, No. 4. pp. 196-203.
@article{289de518af2546a48bbcf0c2f08ecede,
title = "Hormonal A{\cc}idan Endometriyozis",
abstract = "Estrogen is an extremely potent mitogen for endometrium and endometriosis. The product of a single gene named aromatase, synthesizes estrogen. Aromatase is the rate-limiting enzyme for the conversion of C19 steroids to estrogens in a number of human tissues including the ovary. Additionally, the pathologic estrogen-dependent tissues such as breast cancer and endometriosis also produce significant levels of aromatase and local estrogen. The clinical significance of local aromatase activity in endometriotic tissue was exemplified recently by the successful use of an aromatase inhibitor to treat an unusually aggressive and resistant case of recurrent postmenopausal endometriosis. Therefore, aberrant aromatase expression in endometriotic tissue, in contrast to eutopic endometrium, accounts for local biosynthesis of estrogen that promotes the growth of these lesions. The potent estrogen, estradiol is metabolized and thus inactivated by an enzyme termed 17β-hydroxysteroid dehydrogenase (HSD) type 2. Progesterone action is mediated by its receptor subtypes, progesterone receptor (PR)-A and PR-B. Progesterone, on the other hand, inhibits the mitogenic action of estrogen on endometrium and enhances differentiation. These antiproliferative and differentiative effects of progesterone are less pronounced on endometriotic tissue compared with endometrium. Thus, endometriosis is, at least in part, resistant to progesterone action. A number of abnormalities has been found in the expression of aromatase, 17β-HSD type 2 and PR-B/PR-A ratio in endometriotic tissue. These abnormalities and their functional consequences will be discussed in this review article.",
keywords = "17β-hydroxysteroid Dehydrogenase type 2, Aromatase, Aromatase Inhibitors, Endometriosis, Endometrium, Estradiol, Estrogen, Estrogen Biosynthesis, Estrogen metabolism, Estrone, Progesterone, Progesterone receptors",
author = "Bilgin G{\"u}rateş and Ekrem Sapmaz and Gokhan Kilic and H{\"u}sn{\"u} {\cC}elik",
year = "2003",
month = "12",
language = "Undefined",
volume = "17",
pages = "196--203",
journal = "Jinekoloji ve Obstetrik Dergisi",
issn = "1016-5126",
publisher = "Turkish Anaesthesiology and Intensive Care Society",
number = "4",

}

TY - JOUR

T1 - Hormonal Açidan Endometriyozis

AU - Gürateş, Bilgin

AU - Sapmaz, Ekrem

AU - Kilic, Gokhan

AU - Çelik, Hüsnü

PY - 2003/12

Y1 - 2003/12

N2 - Estrogen is an extremely potent mitogen for endometrium and endometriosis. The product of a single gene named aromatase, synthesizes estrogen. Aromatase is the rate-limiting enzyme for the conversion of C19 steroids to estrogens in a number of human tissues including the ovary. Additionally, the pathologic estrogen-dependent tissues such as breast cancer and endometriosis also produce significant levels of aromatase and local estrogen. The clinical significance of local aromatase activity in endometriotic tissue was exemplified recently by the successful use of an aromatase inhibitor to treat an unusually aggressive and resistant case of recurrent postmenopausal endometriosis. Therefore, aberrant aromatase expression in endometriotic tissue, in contrast to eutopic endometrium, accounts for local biosynthesis of estrogen that promotes the growth of these lesions. The potent estrogen, estradiol is metabolized and thus inactivated by an enzyme termed 17β-hydroxysteroid dehydrogenase (HSD) type 2. Progesterone action is mediated by its receptor subtypes, progesterone receptor (PR)-A and PR-B. Progesterone, on the other hand, inhibits the mitogenic action of estrogen on endometrium and enhances differentiation. These antiproliferative and differentiative effects of progesterone are less pronounced on endometriotic tissue compared with endometrium. Thus, endometriosis is, at least in part, resistant to progesterone action. A number of abnormalities has been found in the expression of aromatase, 17β-HSD type 2 and PR-B/PR-A ratio in endometriotic tissue. These abnormalities and their functional consequences will be discussed in this review article.

AB - Estrogen is an extremely potent mitogen for endometrium and endometriosis. The product of a single gene named aromatase, synthesizes estrogen. Aromatase is the rate-limiting enzyme for the conversion of C19 steroids to estrogens in a number of human tissues including the ovary. Additionally, the pathologic estrogen-dependent tissues such as breast cancer and endometriosis also produce significant levels of aromatase and local estrogen. The clinical significance of local aromatase activity in endometriotic tissue was exemplified recently by the successful use of an aromatase inhibitor to treat an unusually aggressive and resistant case of recurrent postmenopausal endometriosis. Therefore, aberrant aromatase expression in endometriotic tissue, in contrast to eutopic endometrium, accounts for local biosynthesis of estrogen that promotes the growth of these lesions. The potent estrogen, estradiol is metabolized and thus inactivated by an enzyme termed 17β-hydroxysteroid dehydrogenase (HSD) type 2. Progesterone action is mediated by its receptor subtypes, progesterone receptor (PR)-A and PR-B. Progesterone, on the other hand, inhibits the mitogenic action of estrogen on endometrium and enhances differentiation. These antiproliferative and differentiative effects of progesterone are less pronounced on endometriotic tissue compared with endometrium. Thus, endometriosis is, at least in part, resistant to progesterone action. A number of abnormalities has been found in the expression of aromatase, 17β-HSD type 2 and PR-B/PR-A ratio in endometriotic tissue. These abnormalities and their functional consequences will be discussed in this review article.

KW - 17β-hydroxysteroid Dehydrogenase type 2

KW - Aromatase

KW - Aromatase Inhibitors

KW - Endometriosis

KW - Endometrium

KW - Estradiol

KW - Estrogen

KW - Estrogen Biosynthesis

KW - Estrogen metabolism

KW - Estrone

KW - Progesterone

KW - Progesterone receptors

UR - http://www.scopus.com/inward/record.url?scp=1642471870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642471870&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 196

EP - 203

JO - Jinekoloji ve Obstetrik Dergisi

JF - Jinekoloji ve Obstetrik Dergisi

SN - 1016-5126

IS - 4

ER -